# Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer

Source: https://onco.cc/trials/nct06291064/  
OnCo record `nct06291064` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of cyclophosphamide, epirubicin, docetaxel, carboplatin and other drugs in triple-negative breast cancer, run by University of Chicago, now recruiting.

## Summary

Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer is a phase 2, interventional study registered as NCT06291064 by University of Chicago, with a registry enrolment figure of 85 participants, started 2025-03-18 and due to reach its primary completion in 2029-06. Interventions recorded: Cyclophosphamide; Epirubicin; Docetaxel; Carboplatin; Breast Surgery; Capecitabine. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Patients with histologically confirmed carcinoma of the female breast with triple-negative status by immunohistochemistry (IHC)". Sites: Nigeria. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: TARMAC
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06291064
- Phase: 2
- Setting: TreAtment Response and Omic-Markers in Triple-Negative Breast CAncer Patients Receiving Standard of Care Chemotherapy (TARMAC)
- Sponsor: University of Chicago
- Enrolled: 85

## Sources

- ClinicalTrials.gov NCT06291064: https://clinicaltrials.gov/study/NCT06291064

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Epirubicin](https://onco.cc/drugs/epirubicin/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06291064.json